Morcellator Versus Resectoscope in the Treatment of Uterine Polyps by Hysteroscopy (RESMO)

August 24, 2018 updated by: University Hospital, Strasbourg, France

Intrauterine pathologies are currently treated by hysteroscopic resection. In this surgical procedure, the intrauterine pathology is resected by a transcervical approach in several fragments using a mono or bipolar cove after distension of the uterine cavity and by endoscopic control. The main risks of this surgery are: uterine perforation and OHIA (operative hysteroscopy intravascular absorption) syndrome. Hysteroscopic morcellators are new intrauterine devices, recently appeared on the French market.

In comparison to classical resectors, morcellators have several theoretical advantages:

  • A smaller instrument diameter with potentially a lower risk of uterine perforation and cervical laceration during the dilatation procedure,
  • The use of physiological serum, eliminating the risk of neurological toxicity of glycine,
  • The risk of electrical accident is canceled (internal or external burns due to leakage current),
  • A decreased risk of air embolism, due to the absence of bubbles' production,
  • The instrument is always under visual control, the perforation risk by the active instrument is therefore very limited,
  • The vision is not obscured by the fragments or by the bubbles,
  • The treatment of pre-ostial pathologies, not always easy in classical resections, could be facilitated,
  • the absence of thermal effect, and therefore a potentially lower endometrial aggression, is interesting in women with reproductive desire,
  • Absence of chips management, limiting the entry and exit movements in the uterine cavity, improving the vision, reducing the infectious and traumatic risks, specially uterine perforation and air embolism,
  • Morcellation could preserve tissues for histological analysis of possible malignancy (compared to techniques using heat, coagulation, vaporization),
  • Easy learning in comparison to the time-consuming learning of classical hysteroscopic resection,
  • Generated additional cost could be partly amortized by reducing operating time and complications.

It seemed useful to study this new technology.

The primary purpose was to compare the time of hysteroscopic treatment of uterine polyps between a hysteroscopic morcellator the UNIDRIVE S III / DrillCut-X II-GYN-Shaver (Integrated Bigatti Shaver IBS), Storz®, and a conventional resectoscope.

The secondary purposes were to compare the efficiency, complications and comfort of these techniques.

Study Overview

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Strasbourg, France, 67000
        • University Hospital, Strasbourg, France

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • All major patients with single endometrial polyp,
  • Confirmed by a diagnostic hysteroscopy
  • Greater than or equal to one centimeter in size with no upper size limit
  • Patient giving informed consent
  • Subject belonging to a social security organisme

Exclusion Criteria:

  • Ongoing pregnancy or breastfeeding
  • Progressive malignant gynecological pathology
  • Evolutionary Genital infection
  • Suspected malignancy before surgery
  • Multiple Polyps
  • Polypoid hyperplasia
  • Associated submucosal myoma
  • Person under guardianship
  • Patient with contraindication to general anesthesia or spinal anesthesia
  • Person in an exclusion period (determined by a previous or ongoing study)
  • Inability to give the eprosn informed information (comprehension difficulties ...)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: morcellation
The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
Active Comparator: standard resection
The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Morcellation or resection time (minutes)
Time Frame: From the cervical dilatation just before introducing the operative device until removal of the operative device assessed up to 25 minutes
From the cervical dilatation just before introducing the operative device until removal of the operative device assessed up to 25 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The completeness of resection or not,
Time Frame: 10 weeks after surgery
10 weeks after surgery
The total operating time (in minutes):
Time Frame: from the beginning of diagnostic hysteroscopy to the end of operative hysteroscopy resection and removal of the operative device, assessed up to 25 minutes
from the beginning of diagnostic hysteroscopy to the end of operative hysteroscopy resection and removal of the operative device, assessed up to 25 minutes
The amount of serum used (mL)
Time Frame: At the end of surgery
At the end of surgery
Perioperative complications,
Time Frame: 10 weeks after surgery
10 weeks after surgery
The quality of vision defined by the operator on a scale of 0 to 5,
Time Frame: At the end of surgery
At the end of surgery
Persistence or not of the disease
Time Frame: 10 weeks after surgery
evaluated by hysteroscopy
10 weeks after surgery
The occurrence of secondary adhesions
Time Frame: 10 weeks after surgery
10 weeks after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Olivier GARBIN, MD, University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2015

Primary Completion (Actual)

July 1, 2018

Study Completion (Actual)

July 1, 2018

Study Registration Dates

First Submitted

June 5, 2015

First Submitted That Met QC Criteria

June 10, 2015

First Posted (Estimate)

June 15, 2015

Study Record Updates

Last Update Posted (Actual)

August 27, 2018

Last Update Submitted That Met QC Criteria

August 24, 2018

Last Verified

September 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 6043

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endometrial Polyps

Clinical Trials on Hysteroscopic morcellation

3
Subscribe